Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets

Executive Summary

US FDA appears generally satisfied that AcelRx fulfilled initial safety concerns cited in October 2017 complete response letter.
Advertisement

Related Content

Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote
Dsuvia's Thumbs Up From US FDA Advisory Panel Is First Positive Vote For An Opioid In 2018
Recent And Upcoming FDA Advisory Committee Meetings
Keeping Track: A CRL For Tlando, An Accelerated Approval For AndexXa, And A Burst Of Supplemental Approvals
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel